Literature DB >> 7060316

Dipyridamol kinetics.

C Mahony, K M Wolfram, D M Cocchetto, T D Bjornsson.   

Abstract

The kinetics of the antiplatelet drug dipyridamole were studied in six normal subjects (three men and three women) who were ages 22 to 34 yr old. Each received 20 mg IV and four also took a 50-mg oral dose. Blood samples were collected after each dose for a period of 3 days and concentrations of dipyridamole were measured by a sensitive and specific high-performance liquid chromatographic assay. Concentrations after the intravenous dose showed a triexponential decline with a terminal half-life of 11.6 +/- 2.2 hr (x +/- SD). Total plasma clearance was 8.27 +/- 1.82 1/hr and the apparent volume of distribution was 141 +/- 51 1. Concentrations rose 6 to 10 hr after intravenous dipyridamole in each female subject, but not in the male subjects. Dipyridamole blood/plasma concentration ratio changed from an average of 0.7 over the first hour to 1.2 after 5 hr after the intravenous dose. There was an absorption lag time ranging from 34 to 75 min after the oral dose; concentrations peaked at about 2 to 2.5 hr after the dose. The percentage of unbound drag in plasma was 0.88 +/- 0.24%. Systemic availability of the end oral dose was 43 +/- 13%. These results suggest widely varying concentrations in patients receiving the drug, and raise questions about the current clinical practice of using empirical dosage schedules.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060316     DOI: 10.1038/clpt.1982.42

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man.

Authors:  D Gregov; A Jenkins; E Duncan; D Siebert; S Rodgers; B Duncan; F Bochner; J Lloyd
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 2.  The clinical importance of electrocardiographic changes during pharmacologic stress testing with radionuclide myocardial perfusion imaging.

Authors:  Elizabeth M Cosmai; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2005 Jul-Aug       Impact factor: 5.952

3.  Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination.

Authors:  S E Akopov; E S Gabrielian
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Reverse screening approach to identify potential anti-cancer targets of dipyridamole.

Authors:  Shu-Min Ge; Dong-Ling Zhan; Shu-Hua Zhang; Li-Qiang Song; Wei-Wei Han
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

5.  Respiratory gating in cardiac PET: Effects of adenosine and dipyridamole.

Authors:  Martin Lyngby Lassen; Thomas Rasmussen; Thomas E Christensen; Andreas Kjær; Philip Hasbak
Journal:  J Nucl Cardiol       Date:  2016-09-07       Impact factor: 5.952

6.  Absence of effect of dipyridamole on renal and platelet function in diabetes mellitus.

Authors:  D M Gibb; D Dunger; M Levin; D Grant; P Jones; T M Barratt
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

7.  Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Authors:  S S Cao; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Efficiency of labelling of red blood cells with technetium-99m after dipyridamole infusion for thallium-201 stress testing.

Authors:  R J Hicks; P Eu; L B Arkles
Journal:  Eur J Nucl Med       Date:  1992

Review 9.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Authors:  Thomas Lenz; Amy Wilson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.